On Tuesday, Shares of The Dow Chemical Company (NYSE:DOW), gained 2.12% to $53.04.
The Dow Chemical Company, declared that Dow AgroSciences Brazil is working with Brazilian farmers from the state of Mato Grosso to implement more sustainable agricultural practices that will generate climate benefits for the mitigation of Rio 2016’s direct carbon footprint.
The Sustainable Agriculture project is a key element of Dow’s innovative “Sustainable Future” program being implemented across Brazil and Latin America, which utilizes energy-efficient technologies and low-carbon solutions to minimize greenhouse gas (GHG) emissions. Through the Sustainable Agriculture project, Dow, in partnership with Farmers Edge, a world leader in precision agronomy, and Irriger, a Brazilian group specialized in irrigation administration, will provide variable rate technology and expertise to farmers in Mato Grosso, one of Brazil’s main ‘breadbaskets’.
The project is designed to minimize environmental impact and optimize productivity in corn and soybean crops through higher yields, better varieties and more targeted pest control administration. Implementation of the precision and variable rate technologies together with seeds and crop protection solutions from Dow is predictable to result in lower rates of synthetic fertilizer application, leading to a reduction in emissions of nitrous oxide. Nitrous oxide is a greenhouse gas (GHG) and is produced as fertilizer decomposes. The reduced GHG emissions from this project will be applied towards Dow’s commitment to mitigate 500,000 tons of carbon dioxide equivalents (CO2eq) for the Rio 2016 Games.
The Dow Chemical Company manufactures and supplies products that are used primarily as raw materials in the manufacture of customer products and services worldwide. It operates through Agricultural Sciences, Consumer Solutions, Infrastructure Solutions, Performance Materials & Chemicals, and Performance Plastics segments.
Shares of The GEO Group, Inc. (NYSE:GEO), inclined 3.06% to $37.05, during its last trading session.
The GEO Group, declared the activation of three company-owned facilities totaling 4,320 beds in Oklahoma, Michigan, and California.
In early June 2015, GEO began the intake of offenders at the 1,940-bed Great Plains Correctional Facility in Hinton, Oklahoma under a 10-year contract with the Federal Bureau of Prisons. In late June 2015, GEO also began the intake of inmates from the State of Vermont at the 1,740-bed North Lake Correctional Facility in Baldwin, Michigan under a five-year agreement with the Vermont Department of Corrections. Under the contract, GEO will provide comprehensive correctional administration services, counting the provision of industry-leading, evidence-based offender rehabilitation programs under the ‘GEO Continuum of Care.’ On July 1, 2015, GEO activated a 640-bed expansion and began the intake process at the Adelanto Detention Facility in Adelanto, California under the existing contractual structure with the City of Adelanto and U.S. Immigration and Customs Enforcement.
George C. Zoley, Chairman of the Board and Chief Executive Officer of GEO, said: “We are very happy with the successful activation and the start of the intake process at our three company-owned facilities in Oklahoma, Michigan, and California. These important activations are indicative of the continued need for correctional and detention bed space across the United States in addition to our company’s ability to provide tailored real estate, administration, and programmatic solutions to our diversified customer base. ”
The GEO Group, Inc. provides government-outsourced services specializing in the administration of correctional, detention, and re-entry facilities, and the provision of community based services and youth services in the United States, Australia, South Africa, the United Kingdom, and Canada.
Finally, Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), ended its last trade with 9.19% gain, and closed at $8.91.
Anthera Pharmaceuticals, declared that it has accomplished the formerly declared underwritten public offering of 3,833,334 shares of its common stock, offered at a price of $7.50 per share, which comprises the exercise in full by the underwriters of their option to purchase 500,000 additional shares of common stock. The aggregate gross proceeds to the Company from the sale of shares in this offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, are about $28.8 million. Anthera intends to use the net proceeds from this offering for clinical research and development and general corporate purposes.
Citigroup Global Markets Inc. and Piper Jaffray & Co. acted as joint book-running managers for the offering. SunTrust Robinson Humphrey acted as co-manager.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
